B CLL

(redirected from B-Cell Chronic Lymphocytic Leukemia)
Also found in: Wikipedia.
AcronymDefinition
B CLLB-Cell Chronic Lymphocytic Leukemia
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
B-cell chronic lymphocytic leukemia and related disorders (monoclonal B-lymphocytosis (MBL) and small lymphocytic lymphoma (SLL)) are defined by the presence of clonal mature B-lymphocytes with typical immunophenotype in peripheral blood, bone marrow and lymphoid organs (WHO, iw-CLL) (6,7) representing one nosologic entity.
Harder et al., "Cytogenetic and molecular characterization of a patient with simultaneous B-cell chronic lymphocytic leukemia and peripheral T-cell lymphoma," American Journal of Hematology, vol.
The report provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Lundin, "Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody)," Leukemia, vol.
The drug is approved for the treatment of refractory B-cell chronic lymphocytic leukemia (2) and also has been used after stem cell (3) and organ transplantations (4).
"We are committed to fully investigate the therapeutic potential of ALXN6000 as a drug therapy for patients with B-cell chronic lymphocytic leukemia and other hematologic and solid-tumor cancers."
The new indication is for first-line treatment of B-cell chronic lymphocytic leukemia (B-CLL), the leading form of adult leukemia.
B-cell chronic lymphocytic leukemia (CLL)4 is the most common leukemia in western countries.
The companies hope to get added approval for Campath as a first-line treatment for B-cell chronic lymphocytic leukemia, a type of blood cancer.
The drug is currently not approved for the treatment of multiple sclerosis but is indicated for treating B-cell chronic lymphocytic leukemia in patients who have been treated with alkylating agents and who have failed fludarabine therapy.